Milestone Pharmaceuticals Files 8-K on Financials
Ticker: MIST · Form: 8-K · Filed: Mar 21, 2024 · CIK: 1408443
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Milestone Pharma dropped an 8-K detailing their financials. Check it out.
AI Summary
Milestone Pharmaceuticals Inc. filed an 8-K on March 21, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 1111 Dr. Frederik-Philips Boulevard, Suite 420, Montréal, Québec, H4M 2X6.
Why It Matters
This filing provides investors with an update on Milestone Pharmaceuticals' financial performance and operational status, which is crucial for assessing the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing (8-K) and does not appear to contain any immediately alarming or significant new information beyond standard reporting requirements.
Key Players & Entities
- Milestone Pharmaceuticals Inc. (company) — Registrant
- March 21, 2024 (date) — Date of earliest event reported
- 1111 Dr. Frederik-Philips Boulevard, Suite 420, Montréal, Québec, H4M 2X6 (address) — Principal executive offices
FAQ
What specific financial information is being reported in this 8-K filing?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was the earliest event reported in this 8-K filing?
The date of the earliest event reported is March 21, 2024.
What is the exact name of the registrant filing this report?
The exact name of the registrant is Milestone Pharmaceuticals Inc.
Where are Milestone Pharmaceuticals Inc.'s principal executive offices located?
Milestone Pharmaceuticals Inc.'s principal executive offices are located at 1111 Dr. Frederik-Philips Boulevard, Suite 420, Montréal, Québec, H4M 2X6.
What is the Commission File Number for Milestone Pharmaceuticals Inc.?
The Commission File Number for Milestone Pharmaceuticals Inc. is 001-38899.
Filing Stats: 454 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-03-21 07:21:46
Filing Documents
- tm249389d1_8k.htm (8-K) — 27KB
- tm249389d1_ex99-1.htm (EX-99.1) — 74KB
- tm249398d1_ex99-1img001.jpg (GRAPHIC) — 4KB
- 0001104659-24-036941.txt ( ) — 292KB
- mist-20240321.xsd (EX-101.SCH) — 3KB
- mist-20240321_lab.xml (EX-101.LAB) — 33KB
- mist-20240321_pre.xml (EX-101.PRE) — 22KB
- tm249389d1_8k_htm.xml (XML) — 4KB
02
Item 2.02. Results of Operations and Financial Condition. On March 21, 2024, Milestone Pharmaceuticals Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023, which also provided a regulatory and corporate update. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated March 21, 2024. 104 Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MILESTONE PHARMACEUTICALS INC. By: /s/Amit Hasija Amit Hasija Chief Financial Officer Dated: March 21, 2024